The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug fruquintinib worldwide, with Hutchmed responsible for sales of the drug in mainland China, Hong Kong and Macau.

Looking up: Hutchmed will receive up to $1.13 billion in total payments. That includes $400 million up front on closing, as well as potential regulatory, development and sales milestone payments, plus royalties on net sales.

Take Note: Fruquintinib was approved for sale in China in September 2018 but has not yet received similar approval elsewhere. Its applications for the U.S., EU and Japan are not expected to be complete until later this year.

Digging Deeper: Founded in 2000, Hutchmed is a biopharmaceutical company owned by Hong Kong billionaire Li Ka-shing that develops and sells innovative cancer drugs. The company had three drugs approved for sale in China at the end of last June, generating revenue of $202 million in the first half of last year. It recorded a net loss of $163 million for the period. In addition, the company has 13 oncology candidates in clinical trials in China, seven of those also in clinical trials in the U.S. and Europe.

Market Reaction: Hutchmed’s Hong Kong-listed shares rose on Thursday, closing up 10.9% at HK$30.60 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…

NEWS WRAP: Nayuki pours up first annual profit

The premium tea chain aims to expand through franchising to boost its growth amid intense competition  By Teri Yu  Premium tea seller Nayuki Holdings Ltd. (2150.HK) on Wednesday reported its first annual profit since…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…